1. Home
  2. GCTK vs RDHL Comparison

GCTK vs RDHL Comparison

Compare GCTK & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GCTK
  • RDHL
  • Stock Information
  • Founded
  • GCTK 2001
  • RDHL 2009
  • Country
  • GCTK United States
  • RDHL Israel
  • Employees
  • GCTK N/A
  • RDHL N/A
  • Industry
  • GCTK Medical/Dental Instruments
  • RDHL Biotechnology: Pharmaceutical Preparations
  • Sector
  • GCTK Health Care
  • RDHL Health Care
  • Exchange
  • GCTK Nasdaq
  • RDHL Nasdaq
  • Market Cap
  • GCTK 5.1M
  • RDHL 6.8M
  • IPO Year
  • GCTK N/A
  • RDHL N/A
  • Fundamental
  • Price
  • GCTK $0.38
  • RDHL $3.02
  • Analyst Decision
  • GCTK
  • RDHL
  • Analyst Count
  • GCTK 0
  • RDHL 0
  • Target Price
  • GCTK N/A
  • RDHL N/A
  • AVG Volume (30 Days)
  • GCTK 1.5M
  • RDHL 142.7K
  • Earning Date
  • GCTK 03-27-2025
  • RDHL 04-07-2025
  • Dividend Yield
  • GCTK N/A
  • RDHL N/A
  • EPS Growth
  • GCTK N/A
  • RDHL N/A
  • EPS
  • GCTK N/A
  • RDHL N/A
  • Revenue
  • GCTK N/A
  • RDHL $3,707,000.00
  • Revenue This Year
  • GCTK N/A
  • RDHL $224.90
  • Revenue Next Year
  • GCTK N/A
  • RDHL $82.69
  • P/E Ratio
  • GCTK N/A
  • RDHL N/A
  • Revenue Growth
  • GCTK N/A
  • RDHL N/A
  • 52 Week Low
  • GCTK $0.31
  • RDHL $3.01
  • 52 Week High
  • GCTK $99.00
  • RDHL $20.28
  • Technical
  • Relative Strength Index (RSI)
  • GCTK 29.14
  • RDHL 17.60
  • Support Level
  • GCTK $0.31
  • RDHL $3.01
  • Resistance Level
  • GCTK $0.39
  • RDHL $3.47
  • Average True Range (ATR)
  • GCTK 0.05
  • RDHL 0.45
  • MACD
  • GCTK 0.15
  • RDHL -0.09
  • Stochastic Oscillator
  • GCTK 45.83
  • RDHL 0.73

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Share on Social Networks: